SEC Form 4
AgomAb Therapeutics NV (AGMB) insider trading
In the 12 months to Oct 26, 2026, 3 AGMB insiders reported open-market purchases of $400.0K across 5 filings; no open-market sales were filed.
Latest filing · Last 12 months · Source: SEC EDGAR · How we count
- Open-market sales
- $0
- 0 filings · 0 insiders
- Open-market purchases
- $400.0K
- 5 filings
Who traded AGMB, and when
- Purchase
AGMB daily close from Feb 6, 2026 to Oct 26, 2026, between $8.23 and $17.82, last $8.84. 0 sale and 5 purchase filings by 3 insiders, marked at their filing dates. David R. Epstein, Director: bought $219.7K across 3 filings, first filed Oct 7, 2026, last Oct 22, 2026. Tim Jasper Knotnerus, Chief Executive Officer: bought $94.4K across 1 filing, first filed Oct 7, 2026, last Oct 7, 2026. Pierre Thadee Victor Kemula, Chief Financial Officer: bought $85.9K across 1 filing, first filed Oct 7, 2026, last Oct 7, 2026.
Largest mark · tap a row for others
David R. Epstein · Director
Filing 1 of 2 within a week · $130,850 total
Purchase $86,350
10,000 shares at $8.64 avg
Filed Oct 7, 2026 · traded Oct 5
Close on filing date $8.80
David R. Epstein · Director
Director
$219.7K boughtTim Jasper Knotnerus · Chief Executive Officer
Chief Executive Officer
$94.4K boughtPierre Thadee Victor Kemula · Chief Financial Officer
Chief Financial Officer
$85.9K boughtOpen-market trades
5 filings in the last 12 months| Insider | Role | Sold | Bought | Filings | Pre-arranged (10b5-1) | Last filed |
|---|---|---|---|---|---|---|
| David R. Epstein | Director | — | $219.7K | 3 | — | |
| Tim Jasper Knotnerus | Chief Executive Officer | — | $94.4K | 1 | — | |
| Pierre Thadee Victor Kemula | Chief Financial Officer | — | $85.9K | 1 | — |
| Filed | Insider | Type | Shares | Avg price | Value | Held after | Source |
|---|---|---|---|---|---|---|---|
traded | David R. Epstein Director | Purchase | 10,000 | $8.88 | $88.8K | 20,000 | |
traded | David R. Epstein Director | Purchase | 5,000 | $8.90 | $44.5K | 15,000 | |
traded | David R. Epstein Director | Purchase | 10,000 | $8.64 | $86.4K | 10,000 | |
traded | Pierre Thadee Victor Kemula Chief Financial Officer | Purchase | 10,000 | $8.59 | $85.9K | 3,000 | |
traded | Tim Jasper Knotnerus Chief Executive Officer | Purchase | 11,000 | $8.58 | $94.4K | 21,823 |
GET /stocks/filings/vX/form-4?tickers=AGMB&filing_date.gte=2025-10-26&sort=filing_date.desc&limit=500{
"status": "OK",
"results": [
{
"tickers": [
"AGMB"
],
"issuer_cik": "0002020932",
"owner_cik": "0001445826",
"accession_number": "0001445826-26-000015",
"form_type": "4",
"filing_date": "2026-10-22",
"period_of_report": "2026-10-21",
"issuer_name": "AgomAb Therapeutics NV",
"issuer_trading_symbol": "AGMB",
"owner_name": "Epstein David R",
"is_director": true,
"is_officer": false,
"is_ten_percent_owner": false,
"is_other": false,
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "Common shares",
"transaction_timeliness": "O",
"aff_10b5_one": false,
"transaction_date": "2026-10-21",
"transaction_code": "P",
"equity_swap_involved": false,
"transaction_shares": 5000,
"transaction_price_per_share": 8.9,
"transaction_acquired_disposed": "A",
"shares_owned_following_transaction": 25000,
"transaction_value": 44500,
"not_subject_to_section_16": false,
"direct_or_indirect": "D",
"footnotes": [
{
"id": "F1",
"description": "The common shares may be represented by American Depositary Shares, each of which currently represents one common share."
}
]
},
{
"tickers": [
"AGMB"
],
"issuer_cik": "0002020932",
"owner_cik": "0001445826",
"accession_number": "0001445826-26-000015",
"form_type": "4",
"filing_date": "2026-10-22",
"period_of_report": "2026-10-21",
"issuer_name": "AgomAb Therapeutics NV",
"issuer_trading_symbol": "AGMB",
"owner_name": "Epstein David R",
"is_director": true,
"is_officer": false,
"is_ten_percent_owner": false,
"is_other": false,
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "Common shares",
"transaction_timeliness": "O",
"aff_10b5_one": false,
"transaction_date": "2026-10-21",
"transaction_code": "P",
"equity_swap_involved": false,
"transaction_shares": 5000,
"transaction_price_per_share": 8.86,
"transaction_acquired_disposed": "A",
"shares_owned_following_transaction": 20000,
"transaction_value": 44300,
"not_subject_to_section_16": false,
"direct_or_indirect": "D",
"footnotes": [
{
"id": "F1",
"description": "The common shares may be represented by American Depositary Shares, each of which currently represents one common share."
}
]
}
]
}
// trimmed to 2 resultsThe response includes every Form 4 record; this page keeps open-market purchases and sales on common stock and removes duplicate joint-filer rows.
How to read this page
- Open-market purchase or sale
- A buy or sell of the company's stock at market price. Grants, option exercises, shares withheld for tax, gifts and employee stock plan purchases are listed separately and not counted.
- Filing date
- Insiders have two business days to report a trade. Totals and the chart use the filing date, when the trade became public.
Frequently asked questions
Has AgomAb Therapeutics NV's CEO sold stock?
No. Tim Jasper Knotnerus (CEO) made no open-market sales filed as CEO in the last 12 months.
How current is AGMB’s insider data?
These are AGMB Form 4 filings from the last year, refreshed daily. The Massive Form 4 API has the full, continuously updated record.
What counts as an open-market buy or sell?
Only purchases and sales at the market price. Option exercises, grants, gifts, and shares withheld for taxes are reported on Form 4 but are left out of the buy and sell totals.
Build with AI
Track AGMB insider trades with your agent
This page joins two Massive endpoints: Form 4 filings and daily prices. Ask an agent to watch for new filings:
Using the Massive API (massive.com/docs/llms.txt), check Form 4 filings for AGMB every day with transaction_code=P and tell me when an insider files an open-market purchase, with their role, shares, price and the filing link.
Nothing on this page is investment advice. All data and content is provided for informational purposes under our Terms of Service.